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Brain-eating amoebae cause devastating infections of central nervous system in 
humans, having a mortality rate of 95%. There are limited effective therapeutic options 
available clinically for treating granulomatous amoebic encephalitis and primary amoebic 
meningoencephalitis caused by Acanthamoeba castellanii and Naegleria fowleri, 
respectively. Here we report for the first time that guanabenz conjugated to gold and silver 
nanoparticles has significant antiamoebic activity against both A. castellanii and N. fowleri. 
Gold and silver conjugated guanabenz nanoparticles were synthesized by one-phase 
reduction method and were characterized by ultraviolet-visible spectrophotometry and atomic 
force microscopy. Both metals were facilely stabilized by the coating of guanabenz which 
was examined by surface plasmon resonance determination. The average size of gold 
nanoconjugated guanabenz was found to be 60 nm, whereas, silver nanoparticles were 
produced in larger size distribution with the average diameter of around 100 nm. Guanabenz 
and its noble metal nanoconjugates exhibited potent antiamoebic effects in the range of 2.5 to 
100 µM against both amoebae. Nanoparticles conjugation enhanced the antiamoebic effects 
of guanabenz, as more potent activity was observed at lower effective concentration (2.5 and 
5 µM) compared to drug alone. Moreover, encystation and excystation assays revealed that 
guanabenz inhibits the interconversion between the trophozoite and cyst forms of A. 
castellanii. Cysticdal effects against N. fowleri were also observed. Notably, pre-treatment of 
A. castellanii with guanabenz and its nanoconjugates exhibited significant reduction in the
host cell cytopathogenicity from 65% to 38% and 2% in case of gold and silver 
nanoconjugates, respectively. Moreover, the cytotoxic evaluation of guanabenz and 
nanoconjugates revealed negligible cytotoxicity against human cells. Guanabenz is already 
approved for hypertension and crosses the blood-brain barrier; the results of our current study 
suggest that guanabenz and its conjugated gold and silver nanoparticles can be repurposed as 
a potential drug for treating brain eating amoebic infections.
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Life threatening infectious diseases are caused by pathogenic free-living amoebae 
(FLA) such as Acanthamoeba species and Naegleria fowleri, which have devastating 
mortality rates.1 FLA are eukaryotic microorganism existing in two or three stages during 
their life cycle. Acanthamoeba species alternate between trophozoites and cysts, while 
additionally Naegleria fowleri is also found in a third stage called flagellate. Acanthamoeba 
castellanii causes life-threatening chronic central nervous system (CNS) disease 
granulomatous amoebic encephalitis (GAE), and the serious eye infection Acanthamoeba 
keratitis (AK). 2 AK is a localized, vision threatening, acute corneal infection that is most 
often encountered in contact lens wearers who maintain poor lens hygiene.3 GAE mostly 
occurs in immunocompromised patients and is characterized by cerebral edema, necrotic 
tissue areas, cortical and ganglial encephalomalacia.4 Following dissemination, 
Acanthamoeba cysts and trophozoites are detected in skin lesions, lungs, prostate and adrenal 
tissues other than CNS.5 On the other hand, acute and haemorrhagic CNS infection, primary 
amoebic meningoencephalitis (PAM) caused by Naegleria fowleri, has been reported in 
healthy individuals partaking in water activities, such as swimming, ablution, or diving.6 
Naegleria fowleri gains access to the brain through the nasal route and causes extensive 
damage to the olfactory nerves and meninges.5 Necrotic neural haemorrhage is observed in 
all parts of the brain along with the detection of amoebic trophozoites, leading to poor 
prognosis of the patients and a 95% mortality rate.7,8
Currently, combination therapy is used to treat brain eating amoebic infections. The 
therapeutic options include different combinations of chlorhexidine, polyhexamethylene 
biguanides for AK,3 sulfadiazine, ketoconazole, fluconazole for GAE and amphotericin B, 
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rifampin, miconazole, and miltefosine for PAM.9 However, these drugs have higher host cell 
cytotoxicity and poor efficacy towards the cyst forms.1,10 Thus, discovery of novel 
antiamoebic compounds having the ability to target both the trophozoite and cyst forms of 
FLA is required for the development of better therapeutic options. 
Use of nanomedicine and repurposing of clinically approved drugs are useful 
strategies to treat brain eating infections. Nanoparticle-conjugated drug formulations have 
offered multiple benefits in the treatment of various diseases.11,12 Gold and silver 
nanoparticles have been studied extensively for their biological and medicinal properties. 
Nanoparticles (NP) are reported to improve drug carrier and delivery systems, bioavailability, 
and chemotherapeutic efficacy. Conjugation of compounds with NPs have exhibited 
antimicrobial, antiviral, antiangiogenic, wound healing and antiamoebic activities.13,14 Due to 
their size (1-500 nm), nanoparticles provide large surface to volume ratios and are permeable 
to cellular membranes for the interaction with biomolecules.15
We have previously reported the potential of guanabenz (GNB) as an antiparasitic 
agent against apicomplexan protozoan parasites Toxoplasma gondii and Plasmodium 
falciparum.16,17 Guanabenz acetate is FDA-approved for the treatment of hypertension. It is 
an 2- adrenergic receptor agonist and has the ability to cross the blood-brain barrier.18 As an 
antiparasitic agent, GNB appears to interfere with translational control mechanisms in 
Toxoplasma and Plasmodium falciparum, and also reduces brain cyst burden in BALB/c 
mice with latent toxoplasmosis.16,17 Given these features of guanabenz, we sought to 
determine whether guanabenz has active against pathogenic A. castellanii and N. fowleri. 
Moreover, GNB conjugated gold and silver nanoparticles (AuNPs and AgNPs) were 
synthesized to determine the enhanced chemotherapeutic effects against A. castellanii and N. 
fowleri. Our findings represent the first demonstration of the antiamoebic activity of GNB 
and its nanoconjugates against brain eating amoebae. 
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Characterization of guanabenz coated gold and silver nanoparticles
Guanabenz was used to stabilize gold as well as silver nanoparticles. After successful 
formation of colloidal gold and silver suspensions with guanabenz, these were characterized 
by ultraviolet-visible spectroscopy and atomic force microscopy. The UV-vis spectra of 
metallic nanoconjugates of guanabenz presented in Fig. 1a shows the presence of 
characteristic surface plasmon resonance band at 380 and 540 nm corresponding to AgNPs 
and AuNPs respectively. The spectra were recorded after subsequent washing of 
nanoparticles obtained by centrifuging at 10000 x g and resuspending in ultrapure deionized 
water. Atomic force microscopy imaging was carried out to determine the morphology of 
these synthesized nanoconjugates. The representative images of GNB-AuNPs and GNB-
AgNPs are presented in Fig. 1b and 1c, respectively. The results show that gold nanoparticles 
were found to be smaller in size and relatively monodispersed as compared to AgNPs, which 
were a mixture of small particles and large aggregates. The size of GNB-AuNPs and GNB-
AgNPs was found to be in the broad range of 50-70 and 50-150 nm, respectively.
Gold and silver conjugated guanabenz nanoparticles exhibited antiamoebic effects 
against Acanthamoeba castellanii
Antiamoebic assays were carried out to determine the effects of GNB alone and GNB 
conjugated nanoparticles against A. castellanii (Fig. 2). Chlorhexidine was used as the 
positive control. GNB alone was tested at the concentrations of 2.5, 5, 10, 25, 50, and 100 
M. The concentrations used for the GNB conjugated with AuNPs and AgNPs were 2.5 and 
5 M. The statistical significance of the effects of drug conjugated nanoparticles on 
Acanthamoeba was evaluated against GNB alone. The results in Figure 2 show that GNB and 
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its conjugated nanoparticles have significant antiamoebic effects against Acanthamoeba. 
However, conjugation of GNB with gold and silver nanoparticles exhibited enhanced and 
significant (*P< 0.05) antiamoebic effect as compared to the drug alone. GNB-AgNPs at 5 
M reduced the viability from 5.9 x 105 to 9.3 x 104 while in case of GNB alone the number 
of amoebae was found to be 3.8 x 105. Furthermore, treatment with bare gold and silver 
nanoparticles did not have any adverse effects as compared to untreated amoebae.
Gold and silver conjugated guanabenz nanoparticles inhibited encystation of 
Acanthamoeba castellanii
A. castellanii trophozoites were incubated in encystation medium with GNB alone or
as metal-conjugated nanoparticles to determine their effects on encystment of A. castellanii. 
The encystation media induced the formation of A. castellanii cysts in negative controls. The 
treatment of amoebic trophozoites with GNB conjugated nanoparticles significantly inhibited 
(*P < 0.05, two-sample t test and two-tailed distribution) the process of encystation, in 
comparison to the amoebae treated with GNB and unconjugated nanoparticles alone (Fig. 3). 
Gold and silver conjugated guanabenz nanoparticles inhibited excystation of 
Acanthamoeba castellanii
The potential of GNB alone and its conjugated nanoparticles were also evaluated 
against the cysts of Acanthamoeba castellanii. The amoebic cysts were dispersed in growth 
medium PYG, which were transformed into healthy trophozoites and enumerated using a 
haemocytometer. The treatment of amoebae with GNB conjugated gold and silver 
nanoparticles significantly inhibited the transformation of cysts into healthy trophozoites (*P 
< 0.05) at 5 M concentration, as compared to GNB and bare nanoparticles alone (Fig. 4). 
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However, 2.5 M concentration of both gold and silver conjugated GNB nanoparticles did 
not show any inhibition in comparison with the respective controls. 
Gold and silver conjugated guanabenz nanoparticles reduced Acanthamoeba mediated 
host cell cytopathogenicity in HaCaT cells
Cytopathogenicity assays were performed to test the effect of guanabenz conjugated 
nanoparticles on A. castellanii infected host cells (Fig. 5). The results revealed that, without 
any drug treatment, A. catellanii destroyed 65% of the host cells. Upon pre-treatment with 
chlorhexidine, the cytopathogenicity was completely diminished. GNB-AgNPs also 
significantly reduced the host cell death to 7.5% and 2.5%, respectively at 2.5 and 5 µM. 
Guanabenz alone did not reduce cytopathogenicity, nor did the GNB-AuNPs when compared 
with AuNPs alone (Fig. 5). These findings are in accordance with the results of the 
antiamoebic assays (Fig. 2).
Gold and silver conjugated guanabenz nanoparticles exhibited antiamoebic effects 
against Naegleria fowleri
The antiamoebic activity of GNB and its nanoconjugates was also evaluated against 
N. fowleri (Fig. 6). Amphotericin B was used as the positive control. The results show a
significant (*P < 0.05, two-sample t test and two-tailed distribution) enhancement in 
antiamoebic activity of GNB conjugated nanoconjugates as compared to GNB alone. GNB 
alone only showed antiamoebic effects at 50 and 100 µM against N. fowleri. However, GNB-
AuNPs and GNB-AgNPs produced potent antiamoebic effects at concentrations as low as 2.5 
µM. Conjugation of gold and silver exhibited equally effective antiamoebic effects as 
compared to gold and silver alone, which did not show any effects on amoebae.
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Gold and Silver conjugated Guanabenz Nanoparticles exhibited Anticystic Effects 
against Naegleria fowleri
The anticystic activities of GNB, GNB-AuNPs and GNB-AgNPs were also evaluated 
against cyst form of N. fowleri (Fig. 7). Amphotericin B was used as the positive control, 
whereas gold and silver alone were used as the negative controls. The results showed that 100 
M concentration of GNB alone induced significant (*P < 0.05, two-sample t test and two-
tailed distribution) anticystic effects as compared to the amoebae alone. However, the same 
effect was observed by the GNB nanoconjugates at 5 M concentration (#P < 0.05, two-
sample t test and two-tailed distribution), exhibiting the greater anticystic activity of GNB 
conjugated nanoconjugates in comparison to GNB alone.
Gold and silver conjugated guanabenz nanoparticles did not exhibit cell cytotoxicity 
against HeLa and HaCaT cells
The in vitro cell cytotoxicity was evaluated against two human cell lines by using 
Lactate dehydrogenase assay and the results are presented in Fig. 8 (a) HeLa cells and (b) 
human keratinocytes HaCaT cells. Consistent with GNB being a safe, FDA-approved drug, 
no significant toxicity was observed on these cell lines; only at 100 M did GNB cause ~30% 
toxicity against HaCaT cells. For the GNB nanoconjugates, virtually no toxicity was 
observed for gold, and only very modest levels of toxicity were observed for silver, all <20% 
in both human cell lines. The silver nanoconjugates of GNB also offered a little protection 
against the nanoparticles alone for HeLa cells. In all cases, the toxicity of GNB conjugated 
nanoparticles never exceeded the degree observed for the nanoparticles alone. 
Different classes of drugs have been used as a curative treatment for brain-eating 
amoebic infections, but they remain ineffective.3,19,20 CNS infections caused by 
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Acanthamoeba and N. fowleri are fatal in almost all cases. The mortality rate exceeding 90% 
underscores the seriousness of lacking effective therapeutic options. Thus, there is an urgent 
need to identify new molecules for treating infections caused by the brain-eating amoebae. 
Drugs used clinically for treating Acanthamoeba infections tend to be resistant towards the 
dormant cyst form.21 Moreover, adverse effects such as host cell cytotoxicity, and inadequate 
drug delivery to the target site, remain major challenges. The synergistic therapy used for the 
treatment of brain eating amoebic infections includes different combinations of 
chlorhexidine, polyhexamethylene biguanides for AK, pentamidines, azoles, sulfadiazine for 
GAE and amphotericin B, rifampin, azoles, and miltefosine for PAM. 
Recently, various classes of natural and synthetic compounds and materials have 
shown potential antiamoebic activity in-vitro and in-vivo. Repurposing of clinically approved 
drugs for other diseases have been of great interest for the treatment against brain eating 
amoebae induced infections. Guanabenz acetate is an FDA-approved drug and is used to treat 
hypertension. It is an agonist for -2 adrenergic receptor and the maximum dose studied is 32 
mg twice a day for patients above 18 years of age.18 Although GNB is well tolerated with few 
side effects, it can cause adverse toxicity among patients with liver impairment. In previous 
studies, we reported the antiparasitic potential of GNB against Toxoplasma, which included 
efficacy against both proliferating (tachyzoite) and encysted (bradyzoite) forms.16 
Importantly, GNB also reduced brain cyst burdens in mice chronically infected with 
Toxoplasma. This might be due, in part, to the ability of guanabenz to cross the blood-brain 
barrier.16 These features prompted our testing of GNB against brain eating amoebae, i.e., 
Acanthamoeba and N. fowleri. Furthermore, we also synthesized nanoconjugates of GNB 
with gold and silver to evaluate the effects against both trophozoites and cyst forms. 
Nanoparticle-conjugated drugs have shown great potential in biomedicine in terms of 
increased efficacy, bioavailability, targeted drug delivery, and theranostics.22 We have 
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previously reported the potential of nanoparticles to enhance antiamoebic activity after the 
conjugation with several compounds, such as chlorhexidine, amphotericin B, cinnamic acid, 
diazepam, phenytoin etc. (Aqeel et al., 2016, Anwar et al., 2018, Anwar et al., 2019b).23-25 
Due to the small size in nanometers, increased solubility and stability, and reduced host cell 
cytotoxicity, nanoparticles have great potential and applications in biomedicine. The most 
frequently used inorganic nanoparticles are gold, silver, iron, cobalt, and titanium oxide.11 
Gold has inert properties and less cytotoxicity, which enables it to be considered as 
nanomaterial of choice for therapeutics. Silver nanoparticles themselves have shown 
antimicrobial activity against a broad spectrum of microbes.26
In addition to its agonistic activity on -2 adrenergic receptors, GNB blocks the 
dephosphorylation of eIF2, thereby disrupting translational control in cells.27 This ability 
may explain its activity against neurodegenerative diseases,28 toxoplasmosis29 and breast 
cancer.30 Disrupting translational control can be an effective strategy to target various stages 
of the life cycle of different pathogens.31 In the current study, antiamoebic assays 
demonstrated the amoebistatic potential of GNB alone, as well as the enhanced activity after 
the conjugation with gold and silver nanoparticles.
The transformation of trophozoites into cyst forms (encystation) and vice versa 
(excystation) involves metabolic changes inside the cellular and metabolic machinery of 
Acanthamoeba.2 In Acanthamoeba, propranolol, a  adrenergic receptors antagonist showed 
reduction in cell viability and encystation along with declined protease activity.32 The 
reduced enumeration of cysts formed during encystation assay after the pre-treatment of 
amoebae with GNB and its nanoconjugates might be due to the action of GNB on adrenergic 
receptors. However, its agonistic or antagonistic activity against the multiple adrenergic 
receptor types has yet to be explored. Upregulated protein methylation has also been reported 
during encystation. The use of inhibitors of cellulase synthase, autophagy and cyst specific 
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cysteine protease have also resulted in inhibition of encystation process. Phosphoglycerate 
dehydrogenase (PGDH) and phosphoserine aminotransferase (PSAT), key mediators of L-
serine biosynthesis pathway are known to have important functions in amoebae.33 L-serine is 
an important intermediate molecule of different metabolic pathways including synthesis of 
sphingomyelins, phospholipids and cerebrosides.34,35 Similar pattern of results was observed 
by the excystation assay proposing the effect of GNB on the metabolism of amoebic cells. 
These studies suggest the possible reason of inhibition of encystation and excystation of 
Acanthamoeba by the action of GNB alone and its nanoconjugates. 
Deng et al., 2015 reported in their study that artemether, an antimalarial agent induced 
apoptosis (PCD) in Acanthamoeba. Furthermore, the proteome analysis revealed that 
artemisinin downregulates PGDH and PSAT.35 This further validates our rationale of 
repurposing of clinically approved drug for finding the acute and cost-effective methods of 
cure for treating brain eating amoebic infections. We have previously reported the potential 
use of CNS drugs such as diazepam and phenytoin against Acanthamoeba and N. fowleri.23 
The evaluation of antiamoebic properties of GNB alone, GNB-AuNPs and GNB-AgNPs 
against N. fowleri also showed the decrease in number of viable amoebae, when compared to 
the untreated amoebic cells. Furthermore, the anticystic activity against N. fowleri was 
evaluated for the first time. GNB and its nanoconjugates were found to be also active against 
cyst form of N. fowleri. As, GNB is FDA approved drug, therefore it showed minor 
cytotoxicity against HeLa and HaCaT cell lines, indicating its broader therapeutic window in 
humans.17 
GNB has also shown to have antiinflammatory activity in-vitro. The increased 
production of interleukin-10 (IL-10) and decreased levels of tumour necrotic factor alpha 
(TNF-) are induced by GNB in lipopolysaccharide (LPS) stimulated lethal model in mice, 
also preventing liver functional impairment and prolonging the mice survival.36 Inhibition of 
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GADD34, an α2-adrenergic receptor agonist, by GNB treatment has shown the improved 
survival rate in human cells, when ER stressors were given.37,38 This suggests the possible 
mechanism of their ability to reduce cell cytopathogenicity. Pre-treatment of Acanthamoeba 
with drug and its conjugated nanoparticles also reduced the host cell pathogenicity in HaCaT 
cells. The current study also reveals the efficacy of GNB conjugated nanoparticles for the 
treatment of brain eating amoebic infections.
Methods
Synthesis of guanabenz conjugated nanoparticles
Guanabenz solution was made in phosphate buffer saline (PBS) and stored at 4 C. 
The nanoparticles were synthesized as described previously.39 The Au-conjugated guanabenz 
nanoparticles were synthesized by mixing 0.1 mM of guanabenz solution and 0.1 mM of 
Potassium gold chloride solution, in the ratios of 1:1, 1:5, and 5:1, and kept on magnetic 
stirring for 15 minutes. The reduction was achieved by adding 50 L of freshly prepared 4 
mM sodium borohydride solution. The conjugation of GNB with AuNPs was indicated by 
change of transparent solution into pink coloured solution. The reaction mixture was kept on 
stirring for 1 hour to attain the maximum yield and stability.  Similar procedure was followed 
for the synthesis of Ag-conjugated guanabenz nanoparticles, but the stock concentration used 
for guanabenz and silver nitrate solutions was 1 mM. Formation of GNB-AgNPs was 
indicated by the appearance of yellowish-brown colour in the reaction mixture. Bare 
nanoparticles (AuNPs and AgNPs alone) were also synthesized by similar method except for 
the addition of any drug or stabilizing agent. Guanabenz nanoconjugates were subjected to 
characterization by UV-Visible spectrophotometric determination of surface plasmon 
resonance bands using Thermo (Evolution 210) spectrophotometer, and morphological 
analysis was carried out on AFM using Agilent (AFM 5500) instrument.
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HeLa cells (cervical cancer cell line, ATCC-CCL-2) and HaCaT cells (human 
keratinocyte cell line) were cultured routinely, in RPMI-1640 medium supplemented with 
FBS (10%), L-glutamine (1%), nonessential amino acids (1%), and antibiotics (1% 
penicillin-streptomycin). The cells were maintained in monolayer form incubated at 37 C in 
a 5% CO2 humidified incubator. Sub culturing was done as per the requirement, according to 
the previously described protocol.40
Acanthamoeba culture cultivation
A. castellanii strain of genotype T4 was purchased from American type tissue
collection (ATCC # 50492). Acanthamoeba were cultured routinely in PYG medium in 75 
cm2 tissue culture flasks and incubated at 30 C under sterile conditions. The amoebae 
cultures in the flasks were replenished with fresh medium every alternate day. Before every 
experiment, medium was removed. The cells were washed with 10 ml PBS, and 10 ml fresh 
PYG medium was added. Then, adhered Acanthamoeba cells were detached by placing the 
flasks on ice for 15 minutes, followed by the gentle tapping. Cells were collected after 
centrifugation (3000 g / 10 min) and seeded for the subsequent experiment. This procedure 
was followed in all the assays.41
Naegleria Culture Cultivation 
N. fowleri were grown in RPMI-1640 medium on the monolayers of HeLa cells as
their food source, in 75 cm2 tissue culture flasks under sterile conditions (37 °C and 5% 
CO2), as reported previously. The clinical isolate of N. fowleri used was isolated from the 
cerebrospinal fluid of the patient and purchased from American type tissue collection (ATCC 
# 30174).40
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Briefly, amoebic trophozoites were seeded in 24 well plate in (5x105 / well / 500 L 
RPMI). Cells were incubated with 2.5 M, 5 M, 10 M, 25 M, 50 M, and 100 M 
concentrations of GNB alone. The concentrations used for GNB-AuNPs and GNB-AgNPs 
were 2.5 M and 5 M. Chlorhexidine (100 M) and Amphotericin B (100 M) were added 
in Acanthamoeba and N. fowleri respectively, as the positive controls. Amoebae alone and 
solvent used were the negative controls. After 24 hours of incubation at 30 C with the 
compounds, the trophozoites were enumerated by trypan blue (0.1 %) exclusion method, 
using a haemocytometer, as reported previously.42
Encystation assay
Acanthamoeba trophozoites were seeded in 24 well plate in (5x105 / well / 500 L / 
PBS), with the GNB alone, GNB-AuNPs and GNB AgNPs. As encystation medium (EM), 
each well was supplemented with 50 mM magnesium chloride and 10% glucose. The cells 
were incubated for 72 hours at 30 C until the observation of cysts formation in the negative 
control (amoebae only with EM), under inverted microscope. Following the incubation, 0.1% 
SDS (sodium dodecyl sulphate) was added in each well to kill the remaining trophozoites. 
The SDS-resistant cysts were counted under an inverted microscope, using a 
hemocytometer.42
Excystation assay
Acanthamoeba castellanii trophozoites were transformed into cysts by their 
harvestation on non-nutrient agar plates. The plates were incubated at 30 C for two weeks. 
Before experiment, the cysts were scraped carefully in PBS with the help of a cell scraper, 
followed by the centrifugation at 5000 g for 10 minutes. The collected cyst pellet was 
dissolved in PYG and number of cysts were counted. For the assay, cysts (1x105/ well /500 
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L PYG) were incubated with the test compounds and incubated at 30 C for 72 hours. 
Following the incubation, the cysts converted into trophozoites were counted by trypan blue 
exclusion method, using hemocytometer.43 
Anticystic assay for N. fowleri
N. fowleri cells were grown on HeLa monolayers as feeder cells. After the complete
consumption of monolayers, the flasks were tapped gently to detach the amoebae and were 
collected by centrifugation at 1260 x g. The cell pellet obtained was resuspended in RPMI-
1640 and transferred into a new 75 cm2 tissue culture flask. The cells were monitored closely 
for two weeks until transformed into cysts form. The cysts were collected by gentle tapping 
of the flasks, followed by the centrifugation. For the experiment, cysts (1x105/ well /500 L 
RPMI) were incubated with GNB and its nanoconjugates at 37 C for 72 hours. After 
incubation time, the remaining viable cysts were counted by trypan blue exclusion method, 
using hemocytometer. 
Acanthamoeba mediated host cell cytopathogenicity assay
Amoebic cells (1x105 / well / 500 L RPMI) were incubated with the GNB alone and 
drug conjugated nanoparticles in 24 well plates for 2 hours at 30 C. After incubation, the 
plates were kept on ice for 20 minutes to detach the adherent cells. All the test samples were 
collected in centrifuge tubes and centrifuged at 5000 g for 10 minutes. The collected cell 
pellets were washed twice with PBS. After washing, 200 µL fresh RPMI were added to the 
obtained cell pellets. These test samples and their respective controls were added to the 
cultured monolayer of HeLa cells in 96 well plates, after old medium was removed.43 To 
determine the cytotoxicity by lactate dehydrogenase (LDH) assay, the HeLa cells with the 
added amoebic cells were incubated for 24 hours in the incubator at 37 C and 5% CO2. After 
24 hours, supernatants (cell-free) were collected and released LDH was measured by using 
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LDH cytotoxicity assay detection kit as per the protocol, using the following formula: % 
cytotoxicity = (absorbance of sample treated well − absorbance of untreated cells) / 
(absorbance of cells treated with Triton X-100 − absorbance of untreated cells) × 100.
Host cell cytotoxicity assay
The cytotoxicity induced by GNB and its conjugated metal nanoparticles was 
measured on two different cell lines. HaCaT and HeLa cells were seeded at a density of more 
than 50% confluency and incubated till the monolayer formation. After the monolayer 
formed, old medium was replaced with fresh RPMI supplemented with the designated 
concentrations of the test compounds and incubated for 24 hours. Following incubation, LDH 
was measured as per the protocol described previously.44
Statistical analysis
The data are represented as mean  standard error, and n =  3. All the experiments 
were performed in duplicate and statistical analysis was performed. Two sample student t test 
was applied to determine the significant difference among the groups with 2 paired 
distribution. The different numeric indicate a statistical difference for at least at P < 0.05, 
while *P < 0.05, **P < 0.01, and ***P < 0.001 with another group.
Conclusion
In conclusion, the current study demonstrates the antiamoebic activity of guanabenz 
against brain eating amoebae A. castellanii and N. fowleri for the first time. Furthermore, the 
conjugation of the drug with gold and silver nanoparticles enhanced the antiamoebic activity, 
suggesting its potential use in nanomedicine for efficient drug delivery and reduced adverse 
effects. However, detailed mechanistic studies are required to elucidate the molecular 
mechanism of action of guanabenz and its gold and silver nanoconjugates against brain eating 
amoebae.
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Figure legends
Figure 1. Guanabenz conjugated gold and silver nanoparticles were characterized by (a) UV-
Vis spectroscopy (Thermo Scientific, Evolution 201) and (b and c) AFM (Agilent, 5500) 
respectively for GNB-AuNPs and GNB-AgNPs. 
Figure 2. Antiamoebic activity of GNB and its conjugated gold and silver nanoparticles was 
evaluated against A. castellanii, as described in Methodology section. In brief, A. castellanii 
(5x105 / well / 500 L RPMI) trophozoites were treated with GNB alone and its 
nanoconjugates, for 24 h, at 30 °C. Number of viable A. castellanii were enumerated by 
trypan blue exclusion assay. The results are representative of three independent experiments 
carried out in duplicates as Mean ± S.E.M. GNB conjugated gold and silver nanoparticles 
exhibited enhanced antiamoebic effects as compared to GNB alone (*P < 0.05, **P < 0.01, 
while ***P < 0.001; two-sample t test and two-tailed distribution). * symbol represents the 
significance of GNB alone as compared to the untreated amoebae, whereas # symbol 
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represents the significance of 2.5 and 5 M concentrations of drug conjugated nanoparticles 
in comparison to the GNB alone.
Figure 3. Encystation of A. castellanii (5x105 / well / 500 L PBS+ Encystation Medium) 
was inhibited by incubation with GNB and its nanoconjugates at 30 °C for 72 h. After 
incubation, 0.1% sodium dodecyl sulfate (SDS) was added to dissolve the remaining 
trophozoites and only amoebic cysts were counted, using a haemocytometer. The results are 
representative of three independent experiments carried out in duplicates as Mean ± S.E.M 
(*P < 0.05, **P < 0.01, while ***P < 0.001; two-sample t test and two-tailed distribution). * 
symbol represents the significance of GNB alone as compared to the untreated amoebae, 
whereas # symbol represents the significance of 2.5 and 5 M concentrations of drug 
conjugated nanoparticles in comparison to the bare nanoparticles and GNB alone.
Figure 4. Anticystic effects of GNB conjugated nanoparticles were observed against cysts of 
A. castellanii (1x105/ well /500 L PYG). Briefly, amoebic cysts were incubated with GNB
alone and its nanoconjugates at 30 °C for 72 h. After incubation, number of trophozoites 
were counted, using a haemocytometer. The results are representative of three independent 
experiments carried out in duplicates as Mean ± S.E.M (*P < 0.05, **P < 0.01, while ***P < 
0.001; two-sample t test and two-tailed distribution). * symbol represents the significance of 
GNB alone as compared to the untreated amoebae, whereas # symbol represents the 
significance of 2.5 and 5 M concentrations of drug conjugated nanoparticles as compared to 
GNB and bare nanoparticles alone.
Figure 5. Pre-treatment of GNB alone and its conjugated gold and silver nanoparticles 
diminished A. castellanii mediated host cells cytotoxicity. Briefly, A. castellanii (1x105 / well 
/ RPMI) trophozoites were treated with GNB alone and its nanoconjugates, for 2 hours, at 30 
Page 24 of 34































































°C. Then the pre-treated amoebae were incubated with HaCaT cells for 24 h at 37 °C in a 
humidified 5% CO2 incubator. Next day, the cytotoxicity was evaluated by using an LDH 
assay kit method (Roche). Negative control values for cytotoxicity assays were obtained by 
incubating HaCaT cells with RPMI-1640 alone were used as the negative controls, whereas 
0.1 % Triton X-100 treated cells were used as positive control depicting 100% cell death. The 
results are representative of three independent experiments carried out in duplicates as Mean 
± S.E.M (*P < 0.05, **P < 0.01, while ***P < 0.001; two-sample t test and two-tailed 
distribution). * symbol represents the significance of GNB alone as compared to the 
untreated amoebae, whereas # symbol represents the significance of 2.5 and 5 M 
concentrations of drug conjugated nanoparticles as compared to GNB and bare nanoparticles 
alone.
Figure 6. Antiamoebic activity of GNB alone and its nanoconjugates was evaluated against 
N. fowleri as explained in the Methods section. Briefly, (5x105 / well / 500 L HeLa + RPMI)
N. fowleri trophozoites were treated with GNB alone and its nanoconjugates, for 24 h, at 37
°C in a 5% CO2 humidified incubator. Number of viable N. fowleri were counted by trypan 
blue exclusion using haemocytometer under an inverted microscope. The results are 
representative of three independent experiments carried out in duplicates as Mean ± S.E.M. 
GNB conjugated gold and silver nanoparticles exhibited enhanced antiamoebic effects as 
compared to GNB alone (*P < 0.05, **P < 0.01, while ***P < 0.001; two-sample t test and 
two-tailed distribution). * symbol represents the significance of GNB alone as compared to 
the untreated amoebae, whereas # symbol represents the significance of 2.5 and 5 M 
concentrations of drug conjugated nanoparticles as compared to GNB and bare nanoparticles 
alone.
Page 25 of 34































































Figure 7. Anticystic effects of GNB alone and its nanoconjugates were evaluated against N. 
fowleri. Briefly, (1x105 / well / 500 L RPMI) N. fowleri cysts were incubated with different 
concentrations of GNB alone, GNB-Au and GNB-Ag for 72 h, at 37 °C in a 5% CO2 
humidified incubator. After incubation time period, number of viable N. fowleri cysts were 
counted by trypan blue exclusion method using haemocytometer under an inverted 
microscope. The results are representative of three independent experiments carried out in 
duplicates as Mean ± S.E.M. GNB conjugated gold and silver nanoparticles exhibited 
enhanced anticystic effects as compared to GNB alone (*or #P < 0.05; two-sample t test and 
two-tailed distribution). * symbol represents the significance of GNB alone as compared to 
the untreated amoebae, whereas # symbol represents the significance of 2.5 and 5 M 
concentrations of drug conjugated nanoparticles as compared to GNB and bare nanoparticles 
alone.
Figure 8. The cytotoxicity of GNB alone and its gold and silver conjugated nanoparticles 
was measured by LDH assay, as described in Methods section, against monolayers of (a) 
HeLa and (b) HaCaT cells. The results demonstrated that GNB and its nanoconjugates were 
non-cytotoxic against both the cell types. Next, cell-free supernatant was collected, and 
cytotoxicity was determined using an LDH assay kit (Roche). Negative control values for 
cytotoxicity assays were obtained by incubating HaCaT cells with RPMI-1640 only, whereas 
0.1 % Triton X-100 treated cells were used as positive control depicting 100% cell death. The 
results showed reduced host-cell cytotoxicity by the treatment of both GNB and its 
nanoconjugates. The results are representative of three independent experiments carried out 
in duplicates as Mean ± S.E.M.
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HaCaT cells + A. castellanii
Figure 5.
Page 31 of 34



































































































Page 32 of 34


































































































Page 33 of 34



































































































Page 34 of 34
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
